Kisselev Alexei F相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia.

高特异性免疫蛋白酶体抑制剂 M3258 可诱导 KMT2A::AFF1 驱动的急性淋巴细胞白血病中的蛋白毒性应激和细胞凋亡

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-025-01657-0

Jenkins Tyler W, Fitzgerald Jacquelyn Elise, Park Jieun, Wilson Addison M, Berry Kristy L, Wong Keith S, Houry Walid A, Lee Irene, Maksimenko Andrey V, Panizzi Peter R, Maxuitenko Yulia Y, Loop Matthew Shane, Mitra Amit K, Kisselev Alexei F

细胞生物学

发表日期：2025

文献求助收藏

Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2

用蛋白酶体抑制剂脉冲处理的细胞中蛋白酶体活性的早期恢复与DDI2无关。

影响因子:6.4

doi:10.7554/eLife.91678

Ibtisam, Ibtisam; Kisselev, Alexei F

细胞生物学

发表日期：2024

文献求助收藏

Site-Specific Proteasome Inhibitors

位点特异性蛋白酶体抑制剂

期刊:Biomolecules

影响因子:4.8

doi:10.3390/biom12010054

Kisselev, Alexei F

发表日期：2021

文献求助收藏

DNA-Histone Cross-Links: Formation and Repair

DNA-组蛋白交联：形成与修复

期刊:Frontiers in Cell and Developmental Biology

影响因子:4.3

doi:10.3389/fcell.2020.607045

Pachva, Manideep C; Kisselev, Alexei F; Matkarimov, Bakhyt T; Saparbaev, Murat; Groisman, Regina

发表日期：2020

文献求助收藏

Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits

基于结构的、对人蛋白酶体亚基具有选择性的荧光底物设计

期刊:Chembiochem

影响因子:2.8

doi:10.1002/cbic.202000375

Maurits, Elmer; Degeling, Christian G; Kisselev, Alexei F; Florea, Bogdan I; Overkleeft, Herman S

发表日期：2020

文献求助收藏

Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits

基于结构的、选择性抑制人蛋白酶体β2c或β2i亚基的抑制剂设计

期刊:Journal of Medicinal Chemistry

影响因子:6.8

doi:10.1021/acs.jmedchem.8b01884

Xin, Bo-Tao; Huber, Eva M; de Bruin, Gerjan; Heinemeyer, Wolfgang; Maurits, Elmer; Espinal, Christofer; Du, Yimeng; Janssens, Marissa; Weyburne, Emily S; Kisselev, Alexei F; Florea, Bogdan I; Driessen, Christoph; van der Marel, Gijsbert A; Groll, Michael; Overkleeft, Herman S

发表日期：2019

文献求助收藏

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

新型β2选择性蛋白酶体抑制剂LU-102与硼替佐米和卡非佐米协同作用，可克服骨髓瘤细胞对蛋白酶体抑制剂的耐药性。

期刊:Haematologica

影响因子:7.9

doi:10.3324/haematol.2014.109421

Kraus, Marianne; Bader, Juergen; Geurink, Paul P; Weyburne, Emily S; Mirabella, Anne C; Silzle, Tobias; Shabaneh, Tamer B; van der Linden, Wouter A; de Bruin, Gerjan; Haile, Sarah R; van Rooden, Eva; Appenzeller, Christina; Li, Nan; Kisselev, Alexei F; Overkleeft, Herman; Driessen, Christoph

细胞生物学

发表日期：2015

文献求助收藏

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

新型β2选择性蛋白酶体抑制剂LU-102可降低IκB的磷酸化水平，并与伊布替尼联合使用时在多发性骨髓瘤细胞中产生高度协同的细胞毒性。

期刊:Cancer Chemotherapy and Pharmacology

影响因子:2.3

doi:10.1007/s00280-015-2801-0

Kraus, Johannes; Kraus, Marianne; Liu, Nora; Besse, Lenka; Bader, Jürgen; Geurink, Paul P; de Bruin, Gerjan; Kisselev, Alexei F; Overkleeft, Herman; Driessen, Christoph

多发性骨髓瘤

细胞生物学

发表日期：2015

文献求助收藏

Proteasome inhibitors: an expanding army attacking a unique target

蛋白酶体抑制剂：一支不断壮大的军队，攻击一个独特的靶点

doi:10.1016/j.chembiol.2012.01.003

Kisselev, Alexei F; van der Linden, Wouter A; Overkleeft, Herman S

发表日期：2012

文献求助收藏

Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib

特异性细胞渗透性蛋白酶体胰蛋白酶样位点抑制剂可选择性地增强骨髓瘤细胞对硼替佐米和卡非佐米的敏感性。

doi:10.1016/j.chembiol.2011.02.015

Mirabella, Anne C; Pletnev, Alexandre A; Downey, Sondra L; Florea, Bogdan I; Shabaneh, Tamer B; Britton, Matthew; Verdoes, Martijn; Filippov, Dmitri V; Overkleeft, Herman S; Kisselev, Alexei F

细胞生物学

发表日期：2011

文献求助收藏